Skip to Content

GSK PLC GSK Stock Quote

| Rating as of


Morningstar‘s Stock Analysis GSK

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Zantac Legal Ruling Represents a Major Win for GSK and Sanofi, in Line With Our Expectations

Damien Conover Sector Director

Analyst Note

| Damien Conover |

Consistent with our expectations, the Multidistrict Litigation, or MDL, Zantac ruling dismissed cases claiming the drug caused cancer. While we don't expect any changes to our fair value estimates for GSK, Sanofi, and other drug firms that have sold the gastroenterology drug Zantac, the market's overreaction in late summer appears to have largely reversed course based on this ruling, and the shares have largely recuperated the over $30 billion in market capitalization lost when significant investor concern over Zantac litigation emerged in August. Even with the rebound, we continue to view the stocks as undervalued, with the market not fully appreciating the growth potential of the firms and their wide moats.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics GSK

Company Profile GSK

Business Description

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

980 Great West Road
Brentford, Middlesex, TW8 9GS, GBR
Industry Drug Manufacturers - General
Employees 90,083

Related Articles GSK

FAQs for GSK PLC Stock

Yes. GSK has a forward dividend yield of 5.14%. See GSK’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

GSK’s market cap is 5.97 Tril.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

GSK’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

GSK’s price/sales is 1.57.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

GSK’s price/forward earnings is 9.94.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

GSK’s price/book is 6.64.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See GSK’s valuation ratios compared to the Market Index.

GSK’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare GSK’s historical performance against its industry peers and the overall market.